Jean-Paul Clozel, Idorsia CEO (AP Images)
October 11, 2021 07:19 AM EDTUpdated 08:45 AM
R&D

Idor­si­a's Fab­ry dis­ease pro­gram flops a PhI­II study, leav­ing its fu­ture un­clear

Max Gelman

Senior Editor

A top pro­gram for Swiss biotech Idor­sia faces a murky fu­ture af­ter flunk­ing a Phase III test.

Idorisa’s drug can­di­date for Fab­ry dis­ease, known as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists ...

Biotech VC firm out­lines plans for $100M fund

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

Gilead­'s Kite un­cou­ples from Fo­s­un in Chi­na as Yescar­ta faces cov­er­age ob­sta­cles

A VC-backed ge­net­ic test­ing start­up to 'con­sid­er' mak­ing an of­fer to buy 23andMe

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times